deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02594371

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer

Sponsor: Athenex, Inc.

Updated 15 times since 2017 Last updated: Aug 2, 2022 Started: Dec 2, 2015 Primary completion: Jul 25, 2019 Completion: Jun 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metastatic Breast Cancer, this trial is completed. The trial is conducted by Athenex, Inc. and has accumulated 15 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~May 2018 · 4 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Mar 2022 · 9 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  5. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

Show 10 earlier versions
  1. Jun 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  5. Sep 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  6. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  7. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  8. Jan 2018 — May 2018 [monthly]

    Recruiting PHASE3

  9. Feb 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Athenex, Inc.
Data source: Athenex, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .